An oral treatment combining dextromethorphan and bupropion has launched in Argentina for adults with major depressive disorder.
In Plain English: The Clinical Takeaway
- Glutamatergic Mechanism: Unlike older drugs targeting serotonin or dopamine, this medication targets glutamate, the brain’s primary excitatory neurotransmitter, to speed up relief.
- Rapid Response: Clinical trials indicate symptom reduction can begin within the first to second week of a two-dose daily regimen.
- Remission Goal: Psychiatrists emphasize that complete remission—eliminating symptoms and restoring functionality—remains the primary benchmark for recovery.
Clinical Trials and the Glutamatergic Mechanism
Major depressive disorder affects approximately 4% of adults in Argentina, alongside a 9% prevalence of anxiety disorders, according to data highlighted by Infobae. Standard antidepressant therapies primarily target monoaminergic neurotransmitters such as serotonin, noradrenalina, and dopamina. The newly introduced therapy breaks from this tradition by incorporating dextromethorphan to activate the glutamate pathway, paired with bupropion.
Dr. Elsa Costanzo, head of the psychiatry service at Fleni, detailed the clinical rationale during a presentation organized by the laboratory Gador. In contrast, the dextromethorphan-bupropion combination offers symptomatic relief during the initial weeks of treatment.
Clinical evaluation of the drug relies on two primary trials. In the GEMINI study, 39.5% of participants receiving the combination achieved symptom remission at six weeks, compared to 17.3% in the placebo group.
| Clinical Trial | Combination Therapy Remission Rate | Control Group Remission Rate | Timeline Observed |
|---|---|---|---|
| GEMINI Study | 39.5% | 17.3% (Placebo) | 6 Weeks |
| ASCEND Study | 46.5% | 16.2% (Bupropion Monotherapy) | 6 Weeks |
Addressing Treatment Resistance and Public Health Gaps
High rates of smoking, gambling, and substance use disorders in Argentina often coexist with or mask underlying depressive symptoms.
The urgency for varied therapeutic interventions stems from documented treatment resistance. Repeated trials with drugs sharing the same pharmacological spectrum frequently increase cronicidad and clinical complexity. Costanzo warned that recurrent treatment failures reduce the likelihood of eventual remission.
To mitigate tolerability issues, the medication utilizes a titration schedule. This protocol aims to balance rapid efficacy against side effects, addressing the high discontinuation rates seen in traditional psychiatric care.
Contraindications & When to Consult a Doctor
Individuals with specific contraindications to bupropion or dextromethorphan, or those taking monoamine oxidase inhibitors (MAOIs), should avoid this treatment.
References
- Infobae: Llegó a la Argentina un tratamiento oral contra la depresión que actúa desde la primera semana: cómo funciona.
- Current Medical Research and Opinion: Expert consensus recommendations on the use of dextromethorphan-bupropion in major depressive disorder.
- Psychological Bulletin: Gender differences in the prevalence of depression across international cohorts.
